Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 2—February 2017
CME ACTIVITY - Dispatch

Risk Factors for Disseminated Coccidioidomycosis, United States

Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (C.D. Odio, B.E. Marciano, S.M. Holland); University of Arizona College of Medicine, Tucson, Arizona, USA (J.N. Galgiani)

Cite This Article

Introduction

CME Logo

This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: January 11, 2017; Expiration date: January 11, 2018

Learning Objectives

Upon completion of this activity, participants will be able to:

1.   Assess clinical and epidemiologic factors of disseminated coccidioidomycosis, based on a case series and review

2.   Determine risk factors for disseminated coccidioidomycosis

3.   Identify genetics underlying host defense against disseminated coccidioidomycosis.

CME Editor

Karen L. Foster, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships: owns stock, stock options, or bonds from Pfizer.

Authors

Disclosures: Camila D. Odio, MD; Beatriz E. Marciano, MD; John N. Galgiani, MD; and Steven M. Holland, MD, have disclosed no relevant financial relationships.

Top

Abstract

Of 150,000 new coccidioidomycosis infections that occur annually in the United States, ≈1% disseminate; one third of those cases are fatal. Immunocompromised hosts have higher rates of dissemination. We identified 8 patients with disseminated coccidioidomycosis who had defects in the interleukin-12/interferon-γ and STAT3 axes, indicating that these are critical host defense pathways.

Coccidioidomycosis is acquired by inhaling spores of Coccidioides immitis. The Centers for Disease Control and Prevention reported 22,401 cases (42.6 cases/100,000 population) in 2011, an increase from 2,265 cases (5.3/100,000) reported in 1998 (1). Although Coccidioides infection usually produces little illness and results in lifelong immunity, 25%–30% of infections result in protracted but self-limited illness; <1% are complicated by dissemination, which is serious and sometimes fatal (24). Diagnosis and treatment remain challenging, especially in persons with disseminated, severe, or chronic disease, where host immunity plays an important role.

During January–March 2014, we reviewed risk factors for dissemination and summarized all coccidioidomycosis cases in patients with primary immunodeficiency (PID). These cases highlight the importance of the interleukin (IL)–12/interferon (IFN)–γ and signal transducer and activator of transcription 3 (STAT3) pathways in host defense. Dissemination of this typically self-limited pathogen should prompt consideration of underlying host genetic factors.

Literature Review

Our systematic literature search resulted in 370 case reports of disseminated coccidioidomycosis (DC) published during 1975–2014 (Technical Appendix). DC was defined as a positive culture or histologic finding from a nonpulmonary site. For comparative purposes, patients were further classified by exogenous immunosuppression, pregnancy, or 1 versus >2 extrapulmonary affected sites.

How the host responds to and contains coccidioidomycosis is unclear, but dissemination occurs in 30%–50% of immunosuppressed hosts. Dissemination can be single-site or multisite, is associated with more severe outcomes than disease limited to the respiratory tract, and requires prolonged treatment (4). Literature review confirms critical interactions of Coccidioides spp. with race/ethnicity, sex, pregnancy, and immune status (Table 1).

The rate of DC is higher for pregnant woman than for the general population (5,6). We found dissemination to the nervous system reported in 37% of pregnant women, approximately one third of whom died (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). Of total deaths, 75% occurred among women during their third trimester; fetal or infant death occurred in 40% of reported cases. Although one third of pregnant women affected were black, survival did not differ by race.

Despite overall improved survival, immunocompromised persons remain at high risk for fatal DC; the crude mortality rate (CMR) was ≈50% for persons immunocompromised by HIV, cancer, organ transplantation, antigraft rejection medications, antiinflammatory biologicals, or chemotherapy (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). CMRs were lower, but still substantial, for patients receiving steroids (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). In HIV-infected exogenously immunocompromised patients, coccidioidomycosis was similar to that in persons without HIV/AIDS. CMRs were lower for persons who were able to stop exogenous immunosuppression. Patients with exogenous immunosuppression were 37% white, 20% Hispanic, and 11% black (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx), similar to the racial/ethnic distribution in DC-endemic areas (California, Arizona: 48% white, 34% Hispanic, 6% black) (7,8). However, these racial/ethnic differences should be interpreted cautiously because race/ethnicity data were unavailable for 24% of patients with exogenous immunosuppression. Regardless of age, immunosuppressed patients were substantially more likely to have extrapulmonary dissemination, require hospitalization, have progressive infection, or die of coccidioidomycosis.

Most (84%) patients with multisite infection were male, and the number of blacks was double that of any other race (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). Additionally, osteomyelitis was more common among blacks (82%) than whites (29%); central nervous system (CNS) infection was more common among whites (59%) than blacks (13%). Hispanics and Asians also had higher rates of osteomyelitis (69% and 60%, respectively) and lower rates of CNS dissemination (38% and 13%, respectively) than whites (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). In contrast, among patients with exogenous immunosuppression, differences in rates of osteomyelitis and CNS infections by race were much smaller (44% of blacks with osteomyelitis vs. 24% of whites and 33% of blacks with CNS infection vs. 21% of whites). These data suggest that different immunologic factors that track with race might variably control susceptibility to DC, osteomyelitis, and CNS disease. However, exogenous immunosuppression apparently overrides these racial/ethnic variations.

Consistent with the demographic characteristics of patients with multisite disease, 83% of those with single-site infection were male (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). Overall, blacks had more single-site osteomyelitis than whites (64% vs. 41%), and whites had more CNS infection than blacks (17% vs. 2%) (https://www.niaid.nih.gov/sites/default/files/HollandTechnicalAppendix.docx). Thus, despite the lower CMR in single-site disease, racial/ethnic differences in infection site were largely consistent between those with single-site and multisite infection.

Single-site and multisite disease accounted for 86% of extrapulmonary Coccidioides infections in blacks and 91% in Asians but for only 56% in whites and 52% in Hispanics. Furthermore, blacks accounted for approximately one third of single-site and multisite infections despite constituting only 6% of the population in coccidioidomycosis-endemic areas. In contrast, only 10% of patients with single-site and multisite disease were Hispanic, even though Hispanics accounted for 35% of the general population in those areas (7). The more population-consistent number of blacks with DC among exogenously immunosuppressed persons and the blunting of racial/ethnic differences with exogenous immunosuppression suggest that exogenous immunosuppression overwhelms intrinsic racial/ethnic variations in host defense. Interpretation of these differences is limited by self-identified race/ethnicity, an imprecise surrogate for ancestral genetic origins. Future studies using established ancestral markers will help solidify associations between coccidioidomycosis infection and race/ethnicity.

We identified 8 cases of proven PID with DC (Table 2). Mutations in the IL-12/IFN-γ or STAT3 pathways were diagnosed in PID patients (Technical Appendix Figure); these patients were younger and more racially/ethnically diverse than immunosuppressed single-site and multisite infected groups. All patients with discrete immune defects had prolonged, refractory infection; some were controlled with exogenous IFN-γ. Of the 8 patients, 3 had no relevant prior medical histories, suggesting that discrete mutations in these pathways might go unrecognized until DC develops.

In Coccidioides-susceptible mice, exogenous IL-12 is protective, whereas disease in resistant strains is exacerbated by its neutralization (13). In vitro, human macrophage killing of phagocytosed Coccidioides depends on IL-12/IFN-γ signaling (14). Furthermore, peripheral blood mononuclear cells from nonimmune (delayed-type hypersensitivity-negative) donors produce significantly less IFN-γ in response to Coccidioides antigens than do such cells from immune (delayed-type hypersensitivity-positive) donors. In vivo, 3 patients with DC improved substantially after therapy with IFN-γ. Immune function studies in 2 of those patients showed blunted IFN-γ–mediated responses (15).

The involvement of STAT3 in resistance to Coccidioides infection is complex. STAT3 is a critical mediator of IL-23 signaling, a cytokine involved in producing IFN-γ, IL-12, and IL-17, all of which are required for immunity to Coccidioides in vivo. It also might be involved downstream of dectin-1, which is required for resistance to Coccidioides in mice and induces the phosphorylation of STAT3.

Conclusions

Risk factors for DC include exogenous immunosuppression (steroids and biologicals), pregnancy, race/ethnicity, and discrete genetic defects. Although racial/ethnic associations with DC were evident in patients without known underlying risks, they were submerged by exogenous immunosuppression.

Functional and genetic studies indicate that the IL-12/IFN-γ axis and STAT3-mediated immunity are central to protection against Coccidioides. We identified mutations affecting these pathways in 8 patients with especially severe or refractory DC, some of whom responded to IFN-γ therapy. Younger patients with severe DC or patients whose illness relapses should be considered for genetic screening for discrete primary immune defects. The discrete defects demonstrated here clearly do not account for all occurrences of coccidioidomycosis in the general population but highlight the importance and nature of genetic control.

Coccidioidomycosis is distinguished by its geography and relative virulence in many persons who otherwise appear immunologically competent. Because most persons in whom DC develops are previously healthy, Coccidioides most likely exploits a very narrow vulnerability. The demonstration that DC has an underlying genetic predisposition indicates that the advent of newer genetic techniques, such as whole exome/genome sequencing, will inevitably identify coccidioidomycosis-specific genetic factors. These, in turn, should enable us to better understand, preempt and treat coccidioidomycosis.

Dr. Odio completed this work while she was a medical student at the Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA. She now an internal medicine resident at Yale–New Haven Hospital. Her research interests include infectious diseases, immunology, and host-pathogen interactions.

Top

Acknowledgments

This study was funded in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), USA.

C.D.O. was funded through the NIH Medical Research Scholars Program, a public-private partnership supported jointly by NIH and generous contributions to the Foundation for the NIH from Pfizer Inc., The Doris Duke Charitable Foundation, The Alexandria Real Estate Equities, Inc., and Mr. and Mrs. Joel S. Marcus, and the Howard Hughes Medical Institute, as well as other private donors. For a complete list, visit the Foundation website (http://fnih.org/work/education-training-0/medical-research-scholars-program).

Top

References

  1. Centers for Disease Control and Prevention (CDC). Increase in reported coccidioidomycosis—United States, 1998-2011. MMWR Morb Mortal Wkly Rep. 2013;62:21721.PubMedGoogle Scholar
  2. Valdivia  L, Nix  D, Wright  M, Lindberg  E, Fagan  T, Lieberman  D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006;12:95862. DOIPubMedGoogle Scholar
  3. Ampel  NM, Giblin  A, Mourani  JP, Galgiani  JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis. 2009;48:1728. DOIPubMedGoogle Scholar
  4. Galgiani  JN, Ampel  NM, Blair  JE, Catanzaro  A, Geertsma  F, Hoover  SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e11246. DOIPubMedGoogle Scholar
  5. Crum  NF, Ballon-Landa  G. Coccidioidomycosis in pregnancy: case report and review of the literature. Am J Med. 2006;119:993.e117. DOIPubMedGoogle Scholar
  6. Bercovitch  RS, Catanzaro  A, Schwartz  BS, Pappagianis  D, Watts  DH, Ampel  NM. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53:3638. DOIPubMedGoogle Scholar
  7. US Census Bureau. State & county QuickFacts [cited 2013 Sep 30]. http://quickfacts.census.gov/qfd/states/04000.html
  8. Noble  JA, Nelson  RG, Fufaa  GD, Kang  P, Shafir  SC, Galgiani  JN. Effect of geography on the analysis of coccidioidomycosis—associated deaths, United States. Emerg Infect Dis. 2016;22:18213. DOIPubMedGoogle Scholar
  9. Powers  AE, Bender  JM, Kumánovics  A, Ampofo  K, Augustine  N, Pavia  AT, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J. 2009;28:6646. DOIPubMedGoogle Scholar
  10. Vinh  DC, Masannat  F, Dzioba  RB, Galgiani  JN, Holland  SM. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis. 2009;49:e625. DOIPubMedGoogle Scholar
  11. Vinh  DC, Schwartz  B, Hsu  AP, Miranda  DJ, Valdez  PA, Fink  D, et al. Interleukin-12 receptor β1 deficiency predisposing to disseminated Coccidioidomycosis. Clin Infect Dis. 2011;52:e99102. DOIPubMedGoogle Scholar
  12. Sampaio  EP, Hsu  AP, Pechacek  J, Bax  HI, Dias  DL, Paulson  ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131:162434. DOIPubMedGoogle Scholar
  13. Magee  DM, Cox  RA. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun. 1996;64:360913.PubMedGoogle Scholar
  14. Ampel  NM, Nesbit  LA, Nguyen  CT, Chavez  S, Knox  KS, Johnson  SM, et al. Cytokine profiles from antigen-stimulated whole-blood samples among patients with pulmonary or nonmeningeal disseminated coccidioidomycosis. Clin Vaccine Immunol. 2015;22:91722. DOIPubMedGoogle Scholar
  15. Kuberski  TT, Servi  RJ, Rubin  PJ. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis. 2004;38:9102. DOIPubMedGoogle Scholar

Top

Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.org. If you are not registered on Medscape.org, please click on the “Register” link on the right hand side of the website to register. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to http://www.ama-assn.org/ama/pub/about-ama/awards/ama-physicians-recognition-award.page. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the certificate and present it to your national medical association for review.

Article Title:
Risk Factors for Disseminated Coccidioidomycosis, United States

CME Questions

1. Your patient is a 56-year-old immunosuppressed man suspected of having disseminated coccidioidomycosis. According to the case series and review by Odio and colleagues, which of the following statements about clinical and epidemiologic factors of disseminated coccidioidomycosis is correct?

A.        The US Centers for Disease Control and Prevention (CDC) reported that cases of coccidioidomycosis doubled from 1998 to 2011

B.        Approximately 15% of cases of coccidioidomycosis disseminate

C.        Dissemination may be single or multisite, is associated with more severe outcomes, and requires prolonged treatment

D.        Coccidioides infection is usually severe and chronic

2. According to the case series and review by Odio and colleagues, which of the following statements about risk factors for disseminated coccidioidomycosis is correct?

A.        Risk factors for coccidioidomycosis dissemination include exogenous immunosuppression (steroids and biologics), pregnancy, race, and specific genetic defects

B.        Nervous system dissemination occurred in 10% of the pregnant women in this series

C.        Mortality rate of disseminated coccidioidomycosis is approximately 25% in those immunocompromised by HIV, cancer, organ transplantation, antigraft rejection medications, anti-inflammatory biologics, or chemotherapy

D.        Blacks were more likely to have central nervous system (CNS) infection, whereas whites were more likely to have osteomyelitis

3. According to the case series and review by Odio and colleagues, which of the following statements about genetics underlying host defense against disseminated coccidioidomycosis is correct?

A.        Interleukin 12/interferon-gamma (IL-12/IFN-γ) and STAT3 axes are critical host defense pathways

B.        IFN-γ therapy was ineffective in severe or refractory disseminated coccidioidomycosis

C.        Older patients with severe or relapsing disseminated coccidioidomycosis should be considered for genetic screening for primary immune defects

D.        The role of STAT3 regarding immunity to Coccidioides is unknown

Activity Evaluation

1. The activity supported the learning objectives.

Strongly Disagree

Strongly Agree

1

2

3

4

5

2. The material was organized clearly for learning to occur.

Strongly Disagree

Strongly Agree

1

2

3

4

5

3. The content learned from this activity will impact my practice.

Strongly Disagree

Strongly Agree

1

2

3

4

5

4. The activity was presented objectively and free of commercial bias.

Strongly Disagree

Strongly Agree

1

2

3

4

5

Top

Cite This Article

DOI: 10.3201/eid2302.160505

1Current affiliation: Yale–New Haven Hospital, New Haven, Connecticut, USA.

Related Links

Table of Contents – Volume 23, Number 2—February 2017

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Steven M. Holland, National Institutes of Health, Bldg 10, Rm 11N248, MSC 1960, Bethesda, MD 20892-1960, USA

Send To

10000 character(s) remaining.

Top

Page created: January 12, 2017
Page updated: January 12, 2017
Page reviewed: January 12, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external